Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset

Sydney multicenter study of Parkinson's disease: Non‐<scp>L</scp>‐dopa–responsive problems dominate at 15 years

M. A. Hely, John G. Morris, Wayne G.J. Reid et al. · Movement Disorders · 2004 · 1K citations

Medicine, Neurology, Pharmacotherapy +13

Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States

Jose Ma. J. Alvir, Jeffrey A. Lieberman, Allan Z. Safferman et al. · New England Journal of Medicine · 1993 · 969 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet · 2013 · 942 citations

Medicine, Pharmacology, Pharmacotherapy +14

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

Masahiko Tatsumi, Karen Groshan, Randy Blakely et al. · European Journal of Pharmacology · 1997 · 938 citations · Full text

Medicine, Pharmacology, Psychiatry +16

Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites

Michael J. Owens, W. Neal Morgan, Susan J. Plott et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 671 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17